Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its first quarter 2014 financial results and ongoing progress with IPI-145, the company’s oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.
“Infinity continues to execute on DUETTS, a worldwide development program of IPI-145, in hematologic malignancies,” commented Adelene Q. Perkins, chief executive officer of Infinity Pharmaceuticals. “We are pleased by the ongoing investigator and patient enthusiasm for DYNAMO, our Phase 2 study of IPI-145 in patients with indolent non-Hodgkin lymphoma, and expect to initiate DYNAMO+R, our Phase 3 combination study in patients with indolent non-Hodgkin lymphoma, in the second half of this year. We are also excited to have initiated in the first quarter patient enrollment in DUO, our Phase 3 study of IPI-145 in patients with chronic lymphocytic leukemia.”
Help employers find you! Check out all the jobs and post your resume.
